Search Results

The pureFLOW solutions are single-use, sterile, ready-to-use dialysis solutions consisting of sodium chloride, potassium chloride, magnesium chloride, calcium chloride (400 series only), sodium bicarbonate, and glucose. The pureFLOW dialysis solutions containing calcium are available in four (4) formulations which differ in potassium chloride concentration. The calcium-free pureFLOW dialysis solutions are available in two (2) formulations which differ in potassium chloride concentration. pureFLOW solutions are single-use, steam sterilized dialysis solutions for use in Continuous Renal Replacement Therapy (CRRT). The pureFLOW solutions are each provided in a 2-compartment bag. One compartment contains 4.75 L of a slightly alkaline bicarbonate solution and the other compartment contains 0.25 L of an acidic electrolyte, glucose solution. The 2 solutions are mixed before use by opening the peel seam between the compartments, yielding 5 L of a ready-to-use sterile solution. The dialysate bags are made of a gas barrier foil, a material manufactured without PVC, latex, or plasticizer. The calcium-containing pureFLOW 400 series solutions are used for treatment modalities using heparin anticoagulation while the calcium-free pureFLOW 500 series solutions are used for treatment modalities using regional citrate anticoagulation.

AI/ML Overview

The provided document, K233159, is an FDA 510(k) summary for the pureFLOW dialysis solutions. This document primarily describes the device, its intended use, and the performance testing conducted to demonstrate substantial equivalence to a predicate device. It does not contain information related to software-based AI/ML device performance or clinical studies using human readers.

Therefore, I cannot fulfill most of the requested points as the information is not present in the provided text. The document explicitly states:

5.8.4. Software Verification and Validation Testing: "Not applicable. The pureFLOW solutions do not contain software."
5.8.6. Clinical Studies: "No clinical studies were performed."

Given this, there is no information on:

Multi-reader multi-case (MRMC) comparative effectiveness studies.
Standalone algorithm performance.
Acceptance criteria for AI/ML performance.
Study design for AI/ML performance, including sample sizes, data provenance, expert qualifications, or adjudication methods for ground truth.
Effect size of human reader improvement with AI assistance.
Training set details for AI/ML models.

However, I can extract information regarding the general performance testing and the context of the device:

Device: pureFLOW dialysis solutions (pureFLOW 402, 400, 406, 401, 502, 504)
Intended Use: As a dialysate in Continuous Renal Replacement Therapy (CRRT).

Here's what can be extracted:

1. A table of acceptance criteria and the reported device performance:

Based on the provided document, the "performance" is demonstrated through various physical, chemical, and biological tests to ensure the product's quality, safety, and functionality as a sterile dialysis solution and its container system. The document lists "Key Performance Specifications/Characteristics" for the chemical components of the solutions. It also details the various "Performance Testing" conducted. While these are not acceptance criteria in the sense of AI/ML metrics (like sensitivity, specificity), they are the performance criteria for this physical device.

Test Conducted	Acceptance Criteria (Implied by "Demonstrate")	Reported Device Performance (Implied by Conclusion of SE)
Chemical Component (Ionic Contribution)	Expected ionic contributions for Sodium (Na+), Potassium (K+), Magnesium (Mg2+), Calcium (Ca2+), Chloride (Cl-), Bicarbonate (HCO3-), and Glucose. (Specific target ranges not provided in this summary, but presumed to meet specifications for safe and effective CRRT dialysate.)	pureFLOW 400 series: Na+ (140 mEq/L), K+ (0, 2, 3, or 4 mEq/L), Mg2+ (1.0 mEq/L), Ca2+ (3.0 mEq/L), Cl- (109, 111, 112, or 113 mEq/L), HCO3- (35 mEq/L), Glucose (5.55).
pureFLOW 500 series: Na+ (133 mEq/L), K+ (2 or 4 mEq/L), Mg2+ (1.5 mEq/L), Ca2+ (0), Cl- (116.5 or 118.5 mEq/L), HCO3- (20 mEq/L), Glucose (5.55).
5 L Bag Hanging	Stability of eyelets (all 3 or single) over 24 hours when hanging on hooks.	Successful (implied by "Testing conducted to support the determination of substantial equivalence" and overall conclusion).
Shipping and Distribution	Integrity and robustness of the bag system packaging within the distribution environment.	Successful.
Primary Bag Welding	Pull tension of foils, fixed seams of primary packaging, peel-stitched primary packaging and secondary packaging.	Successful.
Tube Welding	Pull force of tube welding/seals.	Successful.
HF-Connector and Luer Connector	Torque for removing protective cap, torque of male/female connector, breaking strength of HF-connector cone, leakage and tightness of connectors, pull-out force of connectors and injection ports.	Successful.
Injection Port	Penetration force of the septum and injection port.	Successful.
Eyelet	Pull force strength of the bag eyelet.	Successful.
Gas Barrier Measurement	Integrity of the bag as a CO2 barrier.	Successful.
Sterility	Solution is sterile.	Successful.
Luer-Lock Connector	Tightness after stress crack resistance testing.	Successful.
Temperature and Pressure Resistance of Bag	Resistance of the bag towards temperature and pressure.	Successful.
Biocompatibility (Chemical Characterization, Cytotoxicity, Sensitization, Irritation, Material Mediated Pyrogenicity, Hemocompatibility, Genotoxicity, Toxicological Risk Assessment)	In accordance with ISO 10993-1:2018 and FDA guidance (04 September 2020), endpoints assessed demonstrate biological safety of the container closure system. (Specific criteria for each test not detailed in summary).	Successful.
Human Factors Validation Testing	Device is safe and effective for its intended users, uses, and use environments.	Found to be safe and effective.

2. Sample sizes used for the test set and the data provenance:

The document does not specify exact sample sizes for each of the performance tests (e.g., how many bags were tested for hanging, welding, etc.).
Data provenance (country of origin, retrospective/prospective) is not applicable or provided, as these are primarily laboratory/engineering tests on manufactured product, not clinical data sets.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience):

This is not applicable as the device is not an AI/ML product for which expert-annotated ground truth is required. Performance is demonstrated through physical, chemical, and biological testing.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

Not applicable for the reasons stated above.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

No. The document explicitly states: "No clinical studies were performed." and "The pureFLOW solutions do not contain software." Therefore, no MRMC study was conducted, and this question is not relevant to the described device.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

No. The device does not contain software or an algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

For this type of medical device (physical product, dialysate solution), "ground truth" is established by adherence to predefined engineering specifications, chemical composition limits, sterility requirements, and biocompatibility standards, validated through laboratory testing, rather than clinical outcomes or expert consensus on diagnostic images.

8. The sample size for the training set:

Not applicable. The device does not involve a "training set" in the context of AI/ML.

9. How the ground truth for the training set was established:

Not applicable.

Ask a Question

Ask a specific question about this device

Page 1 of 1